Samuel A Kareff, Asaad Trabolsi, Harris B Krause, Timothy Samec, Andrew Elliott, Estelamari Rodriguez, Coral Olazagasti, Dionysios C Watson, Matias A Bustos, Dave S B Hoon, Stephanie L Graff, Emmanuel S Antonarakis, Sanjay Goel, George Sledge, Gilberto Lopes
Tipifarnib is the only targeted therapy breakthrough for HRAS -mutant ( HRAS mt) recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The molecular profiles of HRAS mt cancers are difficult to explore given the low frequency of HRAS mt. This study aims to understand the molecular co-alterations, immune profiles, and clinical outcomes of 524 HRAS mt solid tumors including urothelial carcinoma (UC), breast cancer (BC), non-small-cell lung cancer (NSCLC), melanoma, and HNSCC. HRAS mt was most common in UC (3...
April 19, 2024: Cancers